Clinical Trials Sponsored by ProGen. Co., Ltd.

Total 10353 results

ProGen. Co., Ltd.

Recruiting

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers

Healthy | Overweight

Korea, Republic of
AtoGen Co. Ltd
ATOGEN AUSTRALIA PTY LTD

Recruiting

Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women

Bacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial Vaginosis

Australia
Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States
Suzhou Abogen Biosciences Co., Ltd.

Recruiting

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors

Solid Tumor, Adult

China
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

COVID-19

Indonesia
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

COVID-19

United Arab Emirates
Biogen
Samsung Bioepis Co., Ltd.

Completed

Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel (BENEFIT)

Rheumatoid Arthritis | Axial Spondyloarthritis

Germany
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Breast Cancer

China
Protgen Ltd

Unknown

Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Walvax Biotechnology Co., Ltd.
Abogen Biosciences Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd.

Recruiting

A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above

COVID-19 | SARS-CoV-2

Indonesia, Mexico
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer

Liver Cancer

China
Protgen Ltd

Unknown

Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer

Colorectal Cancer

China
Protgen Ltd

Unknown

Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure

Pancreatic Cancer

China
Protgen Ltd

Completed

Single-dose Escalation Trial of M2ES in Healthy Volunteer

Cancer
Protgen Ltd

Unknown

Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Protgen Ltd

Unknown

Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

China
Eisai Co., Ltd.
Biogen

Terminated

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1)

Alzheimer's Disease

United States, Argentina, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Slovakia, Spain, United Kingdom
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

China
Chengdu Origen Biotechnology Co., Ltd.

Recruiting

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC (OPTIMA)

Carcinoma of Urinary Bladder, Superficial

Israel, Spain, Italy, Switzerland
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
UroGen Pharma Ltd.

Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Overactive Bladder

Israel
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Interstitial Cystitis | IC

Israel
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
UroGen Pharma Ltd.

Withdrawn

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") (INTIMO2)

Overactive Bladder

Israel
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
UroGen Pharma Ltd.

Withdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG)

Non Muscle Invasive Bladder Cancer

Israel
AryoGen Pharmed Co.

Completed

Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven

Factor VII Deficiency | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Glanzmann's Thrombasthenia

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency

Factor VII Deficiency

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

AryoTrust® (Trastuzumab) Safety Study

Breast Cancer

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors

Hemophilia A With Inhibitor | Hemophilia B With Inhibitor

Iran, Islamic Republic of
AryoGen Pharmed Co.

Completed

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

Hemophilia A or B With Inhibitor

Iran, Islamic Republic of, Turkey
AryoGen Pharmed Co.

Completed

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis (ASQA)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Iran, Islamic Republic of
AryoGen Pharmed Co.

Unknown

Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women

Osteoporosis

Iran, Islamic Republic of

Clinical Trials Sponsored by ProGen. Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations